Injectable Drug Delivery Market

Injectable Drug Delivery Market By Product Type (Self Injector, Needle-Free Injectors, Auto-Injectors, Wearable Injectors, and Insulin Pens), By Technology (Non-smart Injectors and Smart Injectors), and By Region - Global Market Report (2024 to 2034)

Analysis of Injectable Drug Delivery Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Injectable Drug Delivery Market Outlook

The global injectable drug delivery market is estimated to reach US$ 49,446.0 million in 2024 and is forecast to reach a value of US$ 1,10,998.3 million by 2034, with a projected CAGR of 8.4% from 2024 to 2034.

Influential Forces Behind the Injectable Drug Delivery Market Expansion

Injectable drug delivery systems are in high demand because they offer a reliable way to administer pharmaceuticals for the long-term management of chronic conditions like diabetes, cancer, and autoimmune disorders. The demand for injectable drug delivery systems is rising due to the increased attention paid to extensive molecule treatments and biologics, which frequently need to be administered parenterally.

An increase in the prevalence of age-related disorders is correlated with the world's aging population. Treating more common ailments in the elderly population is made possible by injectable drug delivery systems, fueling market expansion. Supportive regulatory frameworks and standards for creating and licensing injectable medication delivery systems facilitate market growth.

Report Attributes Details
Estimated Market Value (2024E) US$ 49,446.0 million
Forecasted Market Value (2034F) US$ 1,10,998.3 million
Global Market Growth Rate (2024 to 2034) 8.4%
Wearable Injectors Segment Growth Rate (2024 to 2034) 9.6%
Multiple Sclerosis Segment Growth Rate (2024 to 2034) 9.4%
North America Market Share (2024) 8.8%
East Asia Market Share (2024) 9.2%
Key Companies Profiled
  • Becton
  • Dickinson and Company
  • Pfizer Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Eli Lilly and Company
  • Baxter International, Inc.
  • Sandoz
  • Terumo
  • Schott AG
  • Gerresheimer
  • Ypsomed
  • Bespak
  • B. Braun Melsungen

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Barriers Hampering the Expansion of Injectable Drug Delivery Technologies

Injectable drug delivery companies can face difficulties due to strict regulatory requirements and the need to comply with multiple health authorities. Developing and testing novel injectable medication delivery technologies entails significant research and development expenses. Introducing unknown items to the injectable drug delivery market can be financially challenging for companies, especially when there is uncertainty regarding the market competition.

The development of injectable drug delivery devices depends on technological advancements. Technological obstacles and hurdles prevent the adoption of innovative technologies like connected health solutions and smart devices. The demand for injectable drug delivery systems, investment decisions, and research funding can all be impacted by economic swings, currency exchange rates, and global economic uncertainty in the healthcare industry.

Country-wise Analysis

The injectable drug delivery market in North America is expected to develop at a CAGR of 8.8% through 2034. Rising product demand in leading countries, especially the United States and Canada, is the primary catalyst behind the spike. The United States tops the market with an estimated share of 83.1% by 2034.

The injectable drug delivery system market in East Asia is expected to advance at a 9.2% CAGR through 2034. China has emerged as the dominant force, with a 59.3% share of the market in East Asia by 2034.

What Does the Future Hold for the Market of Injectable Drug Delivery in North America?

“Biologics Dominance Spurs Market Growth of Injectable Drug Delivery in North America”

Injectable drug delivery methods are growing in popularity in the United States because of strict regulatory frameworks and a well-established healthcare system. Injectable drug delivery systems operate in a dynamic context within the United States healthcare sector, driven by growing demand for self-administration choices and a shift toward biologics. In 2024, the United States injectable drug delivery market is expected to possess an 82.2% share.

Attributes Details
United States Market CAGR 9%
United States Market Size (2024) US$ 14,413 million
Canada Market CAGR 8.3%
Canada Market Size (2024) US$ 2,374 million

Due to the nation's dedication to universal healthcare, injectable drug delivery methods can be used to facilitate widespread patient access. Canada's robust research and development environment plays a significant role in the ongoing advancement of injectable medication delivery techniques, focusing on safety and efficiency. In 2024, Canada is expected to hold a 13.5% injectable drug delivery market share.

What Are the Prospects for Injectable Drug Delivery Market in Asia Pacific?

“Increasing Geriatric Population Contributes to the Injectable Drug Delivery Market Expansion”

The government's focus on innovation and healthcare reform spurs the development of injectable drug delivery systems and creates a vibrant China market. The necessity for effective and patient-friendly solutions is highlighted by the rise in chronic diseases and the aging of the population, which promotes demand for injectable drug delivery systems. In 2024, the China injectable drug delivery system market is expected to gain a 55.8% share.

Attributes Details
China Market CAGR 9.9%
China Market Size (2024) US$ 4,045 million
Japan Market CAGR 8.1%
Japan Market Size (2024) US$ 2,596 million

The demand for injectable medication delivery systems is driven by Japan's aging population, causing a trend toward self-administration and home-based healthcare. The extensive adoption of injectable drug delivery methods in Japan is mainly due to a culture that accepts technical improvements and is highly conscious of healthcare. Japan is expected to grasp a 13.5% injectable drug delivery market share in 2024.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Category-wise Outlook

By 2034, the insulin pens segment is projected to have a 47.4% market share, depending on the product type. In parallel, it is projected that the needle-free injectors segment is likely to attain a growth of 18.6% through 2034, considerably augmenting the resource array and stability of the industry.

With a share of 82.8% through 2034, the non-smart injectors segment establishes its supremacy based on technology. The smart injectors segment is scheduled to come in second with a share of 17.2% throughout the forecast period.

Based on indications, the diabetes segment is expected to dominate with a 52.7% share by 2034. Moreover, the rheumatoid arthritis segment is scheduled to come in second with a share of 10.1% by 2034.

What Factors Propel Insulin Pens to Market Share Leadership?

“Rising Diabetes Cases Surge Insulin Pen Segment Prominence”

Insulin Pens Details
Market Size (2024) US$ 24,717.4 million
Market Share (2024) 50.0%
Needle Free Injectors Details
Market Size (2024) US$ 229.1 million
Market Share (2024) 17.6%

Insulin pens have maintained their leadership in the injectable drug delivery market due to constant technological advances prioritizing user experience and adherence. Insulin pens continue to dominate the market due to the growth in diabetes and knowledge of the advantages of insulin therapy.

Preferred by patients and healthcare providers, insulin pens provide accurate dose management and convenience. Between 2024 and 2034, the insulin pen segment is expected to flourish at a CAGR of 7.9%.

How Does Reliability Make Non-Smart Injectors the Preferred Choice?

“Simplicity In Design Promotes Non-smart Injectors Segment Dominance”

Non-Smart Injectors Details
Market Size (2024) US$ 41,248.9 million
Market Share (2024) 83.4%
Smart Injectors Details
Market Size (2024) US$ 8,197.1 million
Market Share (2024) 16.6%

The healthcare sector's comfort level with tried-and-true technology sustains the market leadership of the non-smart injector segment and encourages continuous preference for these devices. Non-smart injectors are the segment leaders due to their affordability and ease of use, which appeal to a broader spectrum of healthcare professionals.

Due to their established track record, non-smart injectors are the preferred choice for traditional medication administration and continue to hold a substantial market share. From 2024 to 2034, the non-smart injectors segment is expected to thrive at a CAGR of 8.8%.

How Does Diabetes Command the Injectable Drug Delivery Landscape?

“Increasing Awareness Spurs the Dominance of Diabetes Segment in the Market”

Diabetes Details
Market Size (2024) US$ 27,790.9 million
Market Share (2024) 56.2%
Rheumatoid Arthritis Details
Market Size (2024) US$ 4,679.1 million
Market Share (2024) 9.5%

The sector's dominance in the diabetes category is partly attributed to growing awareness and adoption of injectable insulin and other diabetic treatments. With an increase in injectable formulations due to ongoing research and development in diabetes treatments, the share of injectable drug delivery market for the diabetes segment has increased.

Since accurate and convenient insulin administration is required, the high prevalence of diabetes globally is driving demand for injectable drug delivery. The diabetes segment is expected to flourish at a CAGR of 7.7% from 2024 to 2034.

Competitive Analysis

Parenteral injections and implants that assist patients in curing themselves are the main focus of key injectable drug delivery vendors. Prominent injectable drug delivery providers are concentrating on research and development initiatives to introduce pioneering items. To obtain a competitive edge in the injectable drug delivery technology market, these competitors also invest in mergers, acquisitions, and partnerships.

Recent Breakthroughs :

  • West announced a landmark partnership with Corning Incorporated in January 2022 to deliver pharmaceutical injectable drugs. As part of the new partnership, Corning's Valor Glass technology has expanded to enable improved injectable drug packaging and delivery systems for the pharmaceutical industry, improving patient safety and increasing access to life-saving medicines.
  • Novo Nordisk A/S introduced Novopen 6 and Novopen Echo Plus, two smart insulin pens, to the United Kingdom and Ireland market in 2022.
  • Antares Pharma, Inc. announced a phase 1 study on ATRS-1902 for adrenal crisis rescue in September 2021. The program supports the recommended use of a new, patented auto-injector platform that delivers liquid hydrocortisone for adults and adolescents with acute adrenal insufficiency.
  • Becton, Dickinson, and Company released the BD Ultrasafe Plus 2.25 cc Passive Needle Guard for use in pharmaceutical and device goods in November 2021. The novel technique, combined with a Glass Prefillable Syringe, enables the administration of biological solutions in a range of volumes up to 2 ml and viscosities up to 30 cP.
  • Taltz (ixekizumab) injectable was approved by the FDA in August 2019 and is intended for use in individuals with radiographic axial spondyloarthritis (r-axSpA) or active ankylosing spondylitis.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Segmentation of Injectable Drug Delivery Market Research

  • By Product Type :

    • Self-Injector
    • Needle Free Injectors
    • Auto-Injectors
    • Wearable Injectors
    • Insulin Pens
  • By Technology :

    • Non-smart Injectors
    • Smart Injectors
  • By Usage :

    • Disposable Injectors
    • Reusable Injectors
  • By Indication :

    • Anaphylaxis
    • Diabetes
    • Cardiovascular Diseases
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Cancer
    • Others
  • By Distribution Channel :

    • Hospital Pharmacies
    • Drug Stores
    • Retail Pharmacies
    • Online Pharmacies
  • By Region :

    • North America
    • East Asia
    • East Asia
    • South Asia and Pacific
    • Western Europe
    • Eastern Europe
    • The Middle East and Africa

- FAQs -

What Was the Value of The Injectable Drug Delivery Device Market In 2019?

The global injectable drug delivery device market was worth US$ 32,877.2 million in 2019.

What Is the Sales Outlook for Injectable Drug Delivery Market In 2024?

The sales of injectable drug delivery are likely to be valued at US$ 49,446.0 million in 2024.

What Is the Demand Forecast for Injectable Drug Delivery Market?

Demand for injectable drug delivery is expected to reach a market value of US$ 1,10,998.3 million by 2034.

What Is the Adoption Growth Projection for Injectable Drug Delivery Device Market?

The adoption of injectable drug delivery is projected to rise at a CAGR of 8.4% between 2024 and 2034.

At What CAGR Is the Injectable Drug Delivery Market in North America Predicted to Develop?

The North America injectable drug delivery system market is forecasted to expand at a CAGR of 8.8% from 2024 to 2034.

At What CAGR Is the Injectable Drug Delivery Market in East Asia Predicted to Grow?

The East Asia injectable drug delivery system market is forecast to expand at a CAGR of 9.2% through 2034.

- Also of Interest -

Automotive Mobile Accessories Market

Automotive Mobile Accessories Market Analysis by Portable Speakers, Phone Holders, and USB Chargers from 2023 to 2033

Automotive Accelerator Pedal Module Market

Automotive Accelerator Pedal Module Market Share & Trends Analysis, By Product Type (Suspended Pedals, Floor Mounted Pedals), By Vehicle Type (Passenger Cars, Commercial Vehicles), By Sale Channel (OEM, Aftermarket) & By Region Forecast - Global Review 2018 to 2028

Injectable Drug Delivery Market

Schedule a Call